<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575523</url>
  </required_header>
  <id_info>
    <org_study_id>atropinePEI</org_study_id>
    <nct_id>NCT00575523</nct_id>
  </id_info>
  <brief_title>Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy</brief_title>
  <acronym>atropinePEI</acronym>
  <official_title>Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ultrasound guided percutaneous ethanol injection (PEI) is an established method in the
      treatment of hepatocellular carcinoma (HCC) and considered a safe procedure with severe
      complications occurring rarely. Previous studies revealed, that the occurrence of bradycardia
      and sinuatrial blockage is quite frequent during ethanol instillation sometimes accompanied
      by clinical complications such as unconsciousness, respiratory arrest or seizure like
      symptoms. Study purpose is to evaluate whether the use of i.v. Atropine before starting
      ethanol instillation can prevent dysrhythmias during instillation. Study design: randomized,
      placebo controlled, double blinded study. Atropine or saline solution will be administered
      intravenously to 40 patients immediately before starting percutaneous ethanol instillation. A
      6 line ECG with limb leads will be recorded at rest and during ethanol instillation to reveal
      possibly occurring dysrhythmias.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dysrhythmias</measure>
    <time_frame>during percutaneous ethanol instillation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical complications</measure>
    <time_frame>during percutaneous ethanol instillation and consecutive 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Respiratory Arrest</condition>
  <arm_group>
    <arm_group_label>1: Atropine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.</description>
    <arm_group_label>1: Atropine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.</description>
    <arm_group_label>2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hepatoma scheduled for treatment with percutaneous ethanol instillation

        Exclusion Criteria:

          -  contraindication for the administration of atropine like

          -  narrow angle glaucoma

          -  mechanic stenoses of the GI-tract

          -  clinically relevant prostatic hypertrophy

          -  paralytic ileus

          -  myasthenia gravis

          -  severe cerebral sclerosis

          -  acute lung edema

          -  acute myocardial infarction

          -  cardiac insufficiency

          -  hyperthyroidism

          -  patients with contraindication to undergo percutaneous ethanol instillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Ferlitsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Div. of Gastroenterology and Hepatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Ferlitsch A, Kreil A, Bauer E, Schmidinger H, Schillinger M, Gangl A, Peck-Radosavljevic M. Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. Eur J Clin Invest. 2004 Mar;34(3):218-23.</citation>
    <PMID>15025681</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>January 23, 2008</last_update_submitted>
  <last_update_submitted_qc>January 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Arnulf Ferlitsch, MD</name_title>
    <organization>Gastroenterology and Hepatology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>atropine</keyword>
  <keyword>percutaneous ethanol instillation</keyword>
  <keyword>hepatoma</keyword>
  <keyword>bradycardia</keyword>
  <keyword>arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Apnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

